Weight change after (neo)adjuvant chemotherapy in a cohort of breast cancer survivors: Trends by race, hormone positivity, and chemotherapy regimen.

e12018 Background: It is estimated that over 50% of breast cancer survivors gain weight during treatment; patients receiving chemotherapy are at higher risk for weight gain. Previous studies have reported limited information about weight gain with current chemotherapy regimens. Methods: Individual data were collected from a cohort of 98 breast cancer patients treated with neoadjuvant or adjuvant chemotherapy between 2015 and 2017 at Lombardi Comprehensive Cancer Center. Weight was recorded from baseline visits and ≥ 1 visit following completion of chemotherapy. Regimens were grouped into anthracycline- (AC) and non-anthracycline-based (NAC) chemotherapy. Results: Overall, 49% ( n = 48) of patients gained weight after chemotherapy, though African-American patients demonstrated higher baseline BMI. Patients with ER-positive cancers displayed greater weight gain than hormone-negative counterparts ( p = 0.04); PR- or HER2-status was not associated statistically significant changes in weight ( p = 0.12 and 0.82, respectively). Among patients who did gain weight, NAC was associated with greater weight gain (4.47kg) than AC-based regimens (2.54kg) ( p = 0.03). Conclusions: ER positivity and NAC may serve as independent predictors of weight gain during chemotherapy. Further studies might consider further analyzing these trends to demonstrate additional long-term patterns. Baseline and After Chemotherapy BMI (kg/m2) and Weight Change (kilograms and percentage change) (P* derived from ANOVA). [Table: see text]

Download Full-text

A culturally specific dietary plan to manage weight gain among African American breast cancer survivors

Nutrition and Health ◽

10.1177/0260106012459938 ◽

2012 ◽

Vol 21 (2) ◽

pp. 97-105 ◽

Cited By ~ 11

Author(s):

Kathleen A Griffith ◽

Renee Royak-Schaler ◽

Kim Nesbitt ◽

Min Zhan ◽

Adriane Kozlovsky ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Survivors ◽

Breast Cancer Survivors ◽

Vegetable Intake ◽

Survival Rates ◽

Comprehensive Cancer Center ◽

Cancer Center ◽

Daily Consumption ◽

Culturally Specific ◽

Fat Consumption

Breast cancer survival rates are lower in African Americans (AAs) than in Caucasians, owing in part to a higher prevalence of obesity in the former, which increases the risk of recurrence and mortality. The Women’s Intervention Nutrition Study (WINS) found that Caucasian women who followed a low-fat eating plan experienced a lower rate of cancer recurrence than women who maintained their usual diets. The purpose of this study was to test the feasibility of a WINS plan tailored to the cultural needs of AA breast cancer survivors. This feasibility pilot study was conducted at a university National Cancer Institute-designated comprehensive cancer center outpatient clinic with AA breast cancer survivors. The culturally specific WINS (WINS-c) plan included eight individual counseling sessions, five educational group meetings, and follow-up telephone calls over a 1-year period. Outcome measures included dietary fat, triglyceride, insulin and glucose levels, and fruit and vegetable intake. Participants ( n = 8) had a mean age of 61.1 years (standard error of the mean (SEM) 3.1 years) and a mean BMI of 32 kg/m2 (SEM 4.25 kg/m)2. Baseline daily fat consumption decreased from 64.6 g (range 36.8–119.6g) to 44.0 g (21.6–73.4g) at 52 weeks ( p = 0.07). Mean daily consumption of fruits and vegetables increased by 36% and 15%, respectively. Mean triglyceride levels decreased at 12 months ( p < 0.05). Sustained hyperinsulinemia was noted in most participants, including those without diabetes. Mean calcium and vitamin D consumption decreased over the 1-year study period. In AA breast cancer survivors, the WINS-c program resulted in a trend toward reduced fat consumption and may represent a sustainable approach in this population for improvement of diet quality after breast cancer.

Download Full-text

Mindfulness-Based Stress Reduction for Breast Cancer Survivors (MBSR (BC)): Evaluating Mediators of Psychological and Physical Outcomes in a Large Randomized Controlled Trial

10.1101/2020.05.05.20092171 ◽

2020 ◽

Author(s):

Cecile A. Lengacher ◽

L. Forest Gruss ◽

Kevin E. Kip ◽

Richard R. Reich ◽

Manolete S. Moscoso ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Survivors ◽

Perceived Stress ◽

National Cancer Institute ◽

Breast Cancer Survivors ◽

South Florida ◽

Comprehensive Cancer Center ◽

Cancer Center ◽

Cognitive Mechanisms ◽

Link Type

ABSTRACTMBSR(BC) is known to have a positive impact on psychological and physical symptoms among breast cancer survivors (BCS). However, the cognitive mechanisms of “how” MBSR(BC) works are unknown. The purpose of this study, as part of a larger R01 trial, was to test whether positive effects achieved from the MBSR(BC) program were mediated through changes in increased mindfulness, decreased fear of breast cancer recurrence, and perceived stress. Female BCS >21 years diagnosed with Stage 0-III breast cancer were randomly assigned to a 6-week MBSR(BC) or a Usual Care(UC) regimen. Potential outcome mediators were identified by use of an analysis of covariance (ANCOVA), comparing mean values of outcome variables and potential mediating variables followed by mediational and bootstrap analyses. Among 322 BCS (167 MBSR(BC) and 155 UC), fear of recurrence and perceived stress, but not mindfulness, mediated reductions in anxiety and fatigue at weeks 6 and 12, partially supporting our hypothesis of cognitive mechanisms of MBSR(BC).Support: This study was supported by the National Cancer Institute (Award Number 1R01 CA131080-01A2). This work also has been supported in part by the Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. This study protocol was approved by the Institutional Review Board at the University of South Florida to ensure the ethical treatment of participants.Conflict of Interest: The authors have no conflicts to report.Trial Registration:www.ClinicalTrials.gov Registration Number: NCT01177124

Download Full-text

Sleep problems in breast cancer survivors 1–10 years posttreatment

Palliative & Supportive Care ◽

10.1017/s1478951517000311 ◽

2017 ◽

Vol 16 (3) ◽

pp. 325-334 ◽

Cited By ~ 17

Author(s):

Amy E. Lowery-Allison ◽

Steven D. Passik ◽

Matthew R. Cribbet ◽

Ruth A. Reinsel ◽

Barbara O'Sullivan ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Survivors ◽

Breast Cancer Survivors ◽

Sleep Problems ◽

Physical Symptoms ◽

Stage I ◽

Comprehensive Cancer Center ◽

Cancer Center ◽

Vasomotor Symptoms ◽

Poor Sleep

ABSTRACTObjective:Sleep can affect quality of life (QoL) during cancer survivorship, and symptoms related to poor sleep can be exacerbated. We examined the prevalence, severity, and nature of subjective sleep complaints in women surviving stage I–III breast cancer who were 1–10 years posttreatment. We also examined the demographic, medical, physical, and psychosocial correlates of poor sleep in these women in order to identify the subgroups that may be most in need of intervention.Method:A total of 200 patients at a comprehensive cancer center who were 1–10 years posttreatment for primary stage I–III breast cancer with no evidence of disease at the time of enrollment completed a battery of questionnaires on demographics, sleep, physical symptoms, mood, cancer-specific fears, and QoL.Results:The women had a mean age of 57 years (SD = 10.0), with a mean of 63.3 months (SD = 28.8) of post-cancer treatment. Some 38% of these patients were identified as having poor-quality sleep. Women with poor sleep took longer to fall asleep, had more awakenings, and acquired 2 hours less sleep per night than those with good sleep. They also had a lower QoL, greater severity of pain, more concerns about health and recurrence, and increased vasomotor symptoms (p < 0.05). Daytime sleepiness and depression were found to be not significantly correlated with sleep quality.Significance of results:Many breast cancer survivors had severe subjective insomnia, and several breast cancer survivor subgroups were identified as having members who might be most in need of sleep-improvement interventions. Addressing physical symptoms (e.g., vasomotor symptoms and pain) and providing education about the behavioral, social, environmental, and medical factors that affect sleep could result in substantial improvement in the life course of breast cancer survivors.

Download Full-text

Colorectal Cancer Risk in Patients with Breast Cancer Survivors: Evidence from a Comprehensive Cancer Center

The American Journal of Gastroenterology ◽

10.14309/00000434-200910003-01528 ◽

2009 ◽

Vol 104 ◽

pp. S574-S575

Author(s):

Sandhya Shukla ◽

Ashish Shukla ◽

Manoop Bhutani ◽

Sushovan Guha

Keyword(s):

Breast Cancer ◽

Colorectal Cancer ◽

Cancer Risk ◽

Cancer Survivors ◽

Breast Cancer Survivors ◽

Colorectal Cancer Risk ◽

Comprehensive Cancer Center ◽

Cancer Center

Download Full-text

ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy

Clinical Neurophysiology ◽

10.1016/j.clinph.2007.11.011 ◽

2008 ◽

Vol 119 (3) ◽

pp. 533-541 ◽

Cited By ~ 32

Author(s):

Baudewijntje P.C. Kreukels ◽

Hans L. Hamburger ◽

Michiel B. de Ruiter ◽

Frits S.A.M. van Dam ◽

K. Richard Ridderinkhof ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Survivors ◽

Breast Cancer Survivors

Download Full-text

Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e13056 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e13056-e13056

Author(s):

Michael Grimm ◽

Bhuvaneswari Ramaswamy ◽

Maryam B. Lustberg ◽

Robert Wesolowski ◽

Sagar D. Sardesai ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Metastatic Breast ◽

Comprehensive Cancer Center ◽

Cancer Center ◽

Her2 Status ◽

Single Institution ◽

First Line ◽

Response To Chemotherapy ◽

Significant Difference

e13056 Background: Invasive lobular carcinoma (ILC) accounts for only 10-15% of all invasive breast cancers but has distinct clinicopathologic characteristics and genomic profiles. In particular, metastatic lobular cancers (mILC) have unique sites of metastasis and it is unclear if the response to initial endocrine therapy differs from metastatic ductal cancers (mIDC). Therefore we have undertaken a single-institution, retrospective analysis to compare overall outcomes and response to initial endocrine therapy (ET) in patients (pts) with metastatic ILC and IDC. Methods: An IRB approved retrospective review of medical records was conducted evaluating pts treated for metastatic IDC and ILC at The Ohio State University Comprehensive Cancer Center from January 1, 2004 to December 31, 2014. Pts diagnosed with mIDC were matched on age, year of diagnosis, estrogen receptor/progesterone receptor and HER2 status and site of metastasis 2:1 to patients diagnosed with mILC. Overall survival (OS) was defined as the time from metastasis to death or last known follow-up. Progression-free survival (PFS) was defined as time from metastasis to progression on first-line ET. Time to chemotherapy (TTC) was defined as time from starting ET for metastasis to initiation of chemotherapy. Kaplan Meier (KM) methods were used to calculate median OS, PFS and TTC. Results: A total of one hundred sixty one pts with metastatic breast cancer were included in this analysis. The demographic features between the two groups were well balanced and included in the table below. The median OS was 2.6 yrs (95% CI: 1.55, 3.22) for mILC and 2.2 yrs (95% CI: 1.95, 2.62) for mIDC. A subset of 111 patients who started on endocrine therapy were used in the PFS and TTC analyses. The median PFS following first-line ET was 2.2 yrs (95% CI: 0.1.0, 2.7) for mILC and 1.4 yrs (95% CI: 0.91, 1.90) for mIDC. Median TTC was 2.1 yrs (95% CI: 1.71, 4.92) for mILC and 2.4 yrs (95% CI: 1.90, 4.77) for mIDC. There was no statistically significant difference in outcomes between the two groups. Conclusions: Outcomes in patients with ILC and IDC have been varied, with several studies reporting that patients with ILC have worse outcomes and response to chemotherapy. Our retrospective study examining outcomes in mILC in comparison with mIDC showed no difference in OS. Given the concern of resistance to conventional therapies in patients with lobular cancers, it is reassuring to see that the median PFS on first line ET and TTC was similar to metastatic ductal cancers.[Table: see text]

Download Full-text

The Relationship Between Sleep and Weight Change Among Women Diagnosed with Breast Cancer Participating in the Women’s Health Initiative

10.21203/rs.3.rs-906299/v1 ◽

2021 ◽

Author(s):

Sidney Donzella ◽

Kimberly E Lind ◽

Meghan B Skiba ◽

Leslie V Farland ◽

Cynthia A Thomson ◽

...

Keyword(s):

Breast Cancer ◽

Weight Gain ◽

Sleep Quality ◽

Sleep Duration ◽

Cancer Diagnosis ◽

Weight Change ◽

Breast Cancer Survivors ◽

Postmenopausal Breast Cancer ◽

Health Initiative ◽

The Relationship

Abstract Purpose: Short and long sleep duration and poor sleep quality are risk factors for weight gain and cancer mortality. The purpose of this study is to investigate the relationship between sleep and weight change among postmenopausal breast cancer survivors. Methods: Women participating in the Women’s Health Initiative who were diagnosed with incident breast cancer between year 1 and year 3 were included. Self-reported sleep duration was categorized as ≤5 hours (short), 6 hours, 7-8 hours (optimal), and ≥9 hours (long). Self-reported sleep quality was categorized as poor, average, and above average. Post-diagnosis weight change was the difference of weight closest to, but preceding diagnosis, and year 3 weight. We used linear regression to evaluate sleep duration and sleep quality associations with post-diagnosis weight change adjusted for potential confounders. Results: Among 1,156 participants, 63% were weight stable after diagnosis; average weight gain post cancer diagnosis was 3.2 kg. Six percent of women reported sleeping ≤5 hours, 26% reported 6 hours, 64% reported 7-8 hours, and 4% reported ≥9 hours. There were no differences in adjusted estimates of weight change among participants with short duration (0.37kg; 95%CI -0.88, 1.63), or long duration (-0.56kg; 95% CI -2.03, 0.90) compared to optimal duration, nor was there a difference among poor quality (-0.51kg; 95% CI -1.42, 0.41) compared to above average quality. Conclusion: Among postmenopausal breast cancer survivors, sleep duration and quality were not associated with weight change after breast cancer diagnosis. Future studies should consider capturing change in adiposity and to expand beyond self-reported sleep.

Download Full-text